Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2003 May 5;197(9):1125–1139. doi: 10.1084/jem.20020552

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2003, The Rockefeller University Press

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 4. — In vivo clonal fate after SpA treatment. T15i^+/+ splenocytes were labeled with CFSE and adoptively transferred into congenic C57BL/6 recipients. Here, CFSE identifies mononuclear cells derived from the T15i^+/+ donor and dilution of staining intensity identifies cells that have undergone cell division. B cells are identified as B220⁺. The in vivo outcome to treatments with OVA (control), SpA, and immunostimulatory DNA (mitogen) are depicted in cells recovered from the spleens and LNs. Mean values for B cell deletion (−) or proliferation (+) in treatment groups compared with control mice are indicated and determined as described in Table I. The data are representative of three experiments.